You have no items in your shopping cart.
In addition to our selection of pre-validated hit-to-lead stage antibody molecules, Biorbyt provides several mammalian cell display-based antibody engineering platforms. These platforms are designed to optimize candidate antibodies for drug discovery purposes.
Benefits of Mammalian Cell Display Platform
High Expression Identification
Our platform displays candidate antibodies on cell surfaces, facilitating efficient screening for high expressors.
Functional Screening Flexibility
We offer diverse functional assays for screening antibodies based on various functionalities.
Aggregation Mitigation
Our platform can eliminate antibodies prone to aggregation during expression, ensuring product quality.
Antibody Humanization
Biorbyt's humanization platform is designed to produce a range of humanized variants from candidate monoclonal antibody clones while maintaining comparable activity to the parent antibody. Our focus extends beyond antibody affinity, prioritizing humanized antibodies with high expression levels and minimal aggregation—essential for large-scale production of therapeutic antibodies.
Leveraging our mammalian display system, we can identify the most promising humanized variants based on real functional data from candidate antibodies.
Human IgG FR Germline Library
(1~2 weeks)
Expression & Functional Screening
(2~3 weeks)
Optimized IgG Gene Sequencing & Validation
(2~3 weeks)
Affinity Maturation
Biorbyt's Affinity Maturation Service is designed to screen ideal molecules from a large number of antibody variants expressed on mammalian cell surfaces. With this system, the full-length antibody variant library, designed and constructed by AI algorithm, is displayed on the mammalian cell surface. Through FACS sorting, the cells expressing high-affinity binders will be isolated and cloned.
Service Details
Stage | Deliverables | Time |
|---|---|---|
Library construction | Antibody expression report; Library binding report | 1-2 Weeks |
Cell sorting and affinity ranking | Cell sorting report. Affinity ranking report | 2-3 Weeks |
Cloning and sequencing | Sequences of high affinity mAbs | 2-3 Weeks |
Antibody production and affinity measurement | QC report of selected antibodies. SPR report of selected antibodies | 1 Week |
PTM optimization | Analysis of risky PTM sites. Antibody sequences with risky PTM sites optimized | Optional |